Profil bibliographique

Ken Kato

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

14Publications signalées

2Citations signalées

1Affiliations récentes

Institutions déclarées

Domaines associés

Esophageal Cancer Research and TreatmentGastric Cancer Management and OutcomesCancer Immunotherapy and BiomarkersColorectal and Anal CarcinomasPancreatic and Hepatic Oncology Research

Publications récentes

Accès ouvert 2026 conference-abstractOpenAlex

Modeling analysis of RATIONALE-305: Impact of peritoneal metastasis (PM) representation on clinical outcomes in patients (pts) treated with tislelizumab plus chemotherapy (TIS+CT) with gastric cancer/gastroesophageal junction cancer (GC/GEJC).

Mohamad Bassam Sonbol, Sun Young Rha, Rui-Hua Xu, Filippo Pietrantonio et autres

1 citationJournal of Clinical Oncology

Accès ouvert 2026 articleOpenAlex

An open label phase 2 study of total neoadjuvant therapy (TNT) consisting of FLOT with pembrolizumab and short radiation for patients with locally advanced gastroesophageal junction adenocarcinoma (EPOC2301).

Kazuma Sato, I. Nakayama, Masahiro Yura, Akihiro Sato et autres

0 citationsJournal of Clinical Oncology

2026 conference-abstractOpenAlex

Safety and efficacy of zolbetuximab plus chemotherapy for CLDN18.2-positive gastric cancer: A single-center retrospective study.

Shin Kameishi, Hidekazu Hirano, Toshiharu Hirose, Natsuko Okita et autres

0 citationsJournal of Clinical Oncology

Accès ouvert 2026 articleOpenAlex

Randomized controlled phase II trial comparing nivolumab, ipilimumab plus radiotherapy versus nivolumab plus ipilimumab for metastatic or recurrent esophageal cancer: Japan Clinical Oncology Group study JCOG2311 (ART NOUVEAU).

Katsuyuki Sakanaka, Keita Sasaki, T. Tsushima, R. Machida et autres

0 citationsJournal of Clinical Oncology

Accès ouvert 2026 conference-abstractOpenAlex

Phase II study of neoadjuvant chemotherapy with fluorouracil, leucovorin, oxaliplatin and docetaxel for resectable esophageal squamous cell carcinoma: Survival analysis.

Satoru Matsuda, Shun Yamamoto, S. Fukuoka, Takahiro Tsushima et autres

0 citationsJournal of Clinical Oncology

Accès ouvert 2026 conference-abstractOpenAlex

Induction DCF plus nivolumab versus induction DCF for unresectable locally advanced esophageal squamous cell carcinoma.

Ryuichi Morita, Shun Yamamoto, H. Imazeki, Hideaki Takahashi et autres

0 citationsJournal of Clinical Oncology

Accès ouvert 2026 conference-abstractOpenAlex

Conditional recurrence-free survival after curative resection of esophageal cancer: Integrated analysis of individual patient data from 11 randomized controlled trials.

Jun Okui, Satoru Matsuda, Kengo Nagashima, Yasunori Sato et autres

0 citationsJournal of Clinical Oncology

2026 conference-abstractOpenAlex

Associations between ECOG performance status (PS) and patient-reported outcomes (PROs) in patients with gastric or gastroesophageal junction (G/CEJC) adenocarcinoma: Results from the RATIONALE-305 trial.

Marcia Cruz–Correa, Markus H. Moehler, Crystal S. Denlinger, Ken Kato et autres

0 citationsJournal of Clinical Oncology

Accès ouvert 2026 conference-abstractOpenAlex

Proteogenomic interrogation of gastrointestinal neuroendocrine carcinoma.

Hidekazu Hirano, H. Shoji, Toshiharu Hirose, Natsuko Okita et autres

0 citationsJournal of Clinical Oncology

2026 conference-abstractOpenAlex

Short-term outcomes of induction FLOT plus nivolumab for unresectable locally advanced esophageal squamous cell carcinoma in cisplatin-unfit patients.

Ryuichi Morita, Shun Yamamoto, H. Imazeki, Hideaki Takahashi et autres

0 citationsJournal of Clinical Oncology

2026 conference-abstractOpenAlex

Comparison between nivolumab plus ipilimumab, FOLFOX and nivolumab plus FOLFOX therapy as first-line treatment for cisplatin-unfit advanced esophageal squamous cell carcinoma.

Nozomu Ogura, Shun Yamamoto, Ryuichi Morita, H. Imazeki et autres

1 citationJournal of Clinical Oncology

2026 articleOpenAlex

A randomized, double-blinded, international phase III trial comparing HLX22 in combination with trastuzumab and chemotherapy versus trastuzumab and chemotherapy with or without pembrolizumab for first-line treatment for HER2-positive locally advanced or metastatic G/GEJ cancer.

J. A. AJANI, Ken Kato, Futang Yang, Qingyu Wang et autres

0 citationsJournal of Clinical Oncology

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.